This result suggests that antagonizing the vascular endothelial growth factor receptor (VEGFR) pathway be a useful strategy for malignant PEComas, along with the MTOR pathway inhibition that had recently been approved for the rare tumor. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.